Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | IAPP | P10997 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17417363 | 0.89 | PTGER4 (0.39) | PTGER4MAPTMAPK1CYP1A2ADORA2A | |
| SCHEMBL19584584 | 0.88 | CYP1A2 (0.48) | MAPTCTSLCTSBCYP1A2GRM5 | |
| SCHEMBL28516114 | 0.77 | MAPT (0.41) | PTGER4MAPTMAPK1CYP1A2GAA | |
| SCHEMBL17429955 | 0.73 | TLR8 (0.35) | GRM5 | |
| SCHEMBL19584784 | 0.72 | CYP1A2 (0.51) | MAPTCYP1A2GRM5GAANPC1 | |
| SCHEMBL23362438 | 0.71 | MAPT (0.46) | PTGER4MAPTMAPK1CYP1A2GAA | |
| SCHEMBL23320395 | 0.70 | CXCR5 (0.38) | NPC1CYP3A4RAB9ASMN1; SMN2 | |
| SCHEMBL29100978 | 0.70 | MAPT (0.43) | PTGER4MAPTMAPK1CYP1A2ADORA2A | |
| SCHEMBL24848540 | 0.70 | MAPT (0.43) | PTGER4MAPTMAPK1CYP1A2GAA | |
| SCHEMBL14982165 | 0.70 | MAPT (0.45) | PTGER4MAPTMAPK1CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | NXERA PHARMA UK LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | NXERA PHARMA UK LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3455212-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | Heptares Therapeutics Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-9822124-B2 | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822124-B2 | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2016010897-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016010897-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160009726-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20160009726-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009726-A1 | BICYCLIC HETEROAROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | PTGER4 4061/4885MAPT 3881/4885MAPK1 496/4885 |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | PTGER4 434/4885MAPT 2785/4885MAPK1 2478/4885 |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | PTGER4 434/4885MAPT 2785/4885MAPK1 2478/4885 |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | PTGER4 550/4885MAPT 1446/4885MAPK1 2160/4885 |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | PTGER4 550/4885MAPT 1446/4885MAPK1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.